EP Patent

EP3394081A1 — Polymorphic crystalline forms of obeticholic acid

Assigned to Intercept Pharmaceuticals Inc · Expires 2018-10-31 · 8y expired

What this patent protects

The present application relates to crystalline forms A, D, F, G and I of obeticholic acid. These crystalline forms are useful in the production of Obeticholic acid (in particular its purification), which is a drug useful for the treatment or prevention of a FXR mediated disease o…

USPTO Abstract

The present application relates to crystalline forms A, D, F, G and I of obeticholic acid. These crystalline forms are useful in the production of Obeticholic acid (in particular its purification), which is a drug useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3394081A1
Jurisdiction
EP
Classification
—
Expires
2018-10-31
Drug substance claim
No
Drug product claim
No
Assignee
Intercept Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.